

SAFEGUARD SCIENTIFICS INC

Form 8-K

August 27, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported) **August 27, 2009**

**Safeguard Scientifics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Pennsylvania**                      **1-5620**                      **23-1609753**  
(State or Other Jurisdiction      (Commission                      (IRS Employer  
of Incorporation)                      File Number)                      Identification  
No.)

**435 Devon Park Drive, Building 800, Wayne, PA**      **19087**  
(Address of Principal Executive Offices)                      (Zip Code)

Registrant's telephone number, including area code **610-293-0600**

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**ITEM 8.01. Other Events**

On August 27, 2009, the Company announced that Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc., wholly owned subsidiaries of the Company, had completed the sale of a total of 16 million shares of the common stock of Clariant, Inc. held by such subsidiaries in an underwritten public offering. The shares were sold pursuant to an effective registration statement filed with the Securities and Exchange Commission. The underwriters have a 30-day option to purchase up to an additional 2.4 million shares. The press release dated August 27, 2009, is attached as Exhibit 99.1 to this report.

**ITEM 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release dated August 27, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Safeguard Scientifics, Inc.

Dated: August 27, 2009 By: /s/ BRIAN J. SISKO  
Brian J. Sisko  
Senior Vice President and General Counsel